Singular Genomics Pronounces Formation of Scientific Advisory Board

Singular Genomics Systems, Inc.

Singular Genomics Techniques, Inc.

LA JOLLA, Calif., Could 10, 2022 (GLOBE NEWSWIRE) — Singular Genomics Techniques, Inc. (Nasdaq: OMIC), an organization leveraging novel next-generation sequencing (NGS) and multiomics applied sciences to empower researchers and clinicians the means to behave, as we speak introduced the formation of its Scientific Advisory Board (SAB). The SAB features a distinguished group of educational and trade specialists who will advise on the corporate’s product and repair choices and analysis and improvement pipeline.

“We’re thrilled to announce the launch of our Scientific Advisory Board and are privileged to work with such achieved leaders in science and medication,” stated Eli Glezer, Ph.D., Founder and Chief Scientific Officer of Singular Genomics and newly appointed president of the SAB. “The experience of this group in DNA sequencing, human genetics, oncology and immunology will likely be a useful useful resource as we develop the purposes of our G4 sequencing system and develop the PX platform as a software highly effective for area biology.

Singular’s SAB members embrace:

  • David L. Barker, Ph.D., member of the board of administrators of Singular Genomics, AmideBio and Aspen Neuroscience, scientific advisor of Luna DNA and member of the board of administrators and president of Bionano Genomics. Dr. Barker beforehand served as Illumina’s Vice President and Chief Scientific Officer, whereas additionally serving on its Scientific Advisory Board. Throughout his educational profession, Dr. Barker performed interdisciplinary analysis in neurobiology as a postdoctoral fellow at Harvard Medical Faculty, assistant professor on the College of Oregon, and affiliate professor at Oregon State College. Dr. Barker holds a BS with Honors in Chemistry from the California Institute of Expertise and a Ph.D. in Biochemistry from Brandeis College.

  • Lawrence Fong, MD, Efim Guzik Distinguished Professor in Most cancers Biology on the Helen Diller Household Complete Most cancers Heart on the College of California, San Francisco (UCSF); co-director of the Parker Institute of Most cancers Immunotherapy at UCSF; Co-Lead of the Most cancers Immunity and Immunotherapy Program at UCSF Most cancers Heart. Dr. Fong can also be a physician-scientist within the Division of Medication, Division of Hematology/Oncology at UCSF, the place he directs each a translational analysis program and an NIH-funded analysis laboratory. Dr. Fong’s analysis focuses on the mechanisms underlying medical response and resistance to immunotherapies. This work contains monitoring antigen-specific T cell responses in handled most cancers sufferers and growing biomarkers related to medical outcomes. Dr. Fong has acquired a number of awards, together with the NIH Excellent Investigator Award. Dr. Fong acquired his BA from Columbia and his MD from Stanford, and educated in inner medication on the College of Washington, in addition to an oncology fellowship and postgraduate coaching at Stanford in 2002.

  • David H. Ledbetter, Ph.D., FACMG, DABMGG, Chief Medical & Analysis Officer at Unified Affected person Community, Inc. Dr. Ledbetter additionally served as Govt Vice President and Founding Chief Scientific Officer at Geisinger, the place he helped lead their MyCode biobank/genomics venture – one of many largest on this planet. Dr. Ledbetter’s present analysis focuses on leveraging digital longitudinal well being info with large-scale DNA sequencing to find out the medical utility and cost-effectiveness of precision medication approaches in actual life system settings. well being. Dr. Ledbetter is internationally acknowledged for his analysis into the genetic foundation of neurodevelopmental issues in youngsters, having found the genetic reason behind Prader-Willi syndrome and Miller-Dieker syndrome early in his profession. Dr. Ledbetter graduated from Tulane College and earned his Ph.D. on the College of Texas-Austin.

  • Elaine Mardis, Ph.D., Board Member of Singular Genomics; Co-Govt Director of the Institute for Genomic Medication at Nationwide Kids’s Hospital and holder of the Steve and Cindy Rasmussen Endowed Chair in Genomic Medication. Dr. Mardis can also be a professor of pediatrics at The Ohio State College Faculty of Medication. As well as, Dr. Mardis serves on Qiagen’s Supervisory Board, Science and Expertise Committee, and Compensation and Human Sources Committee. Dr. Mardis is an internationally acknowledged pioneer researcher within the subject of most cancers genomics. He focuses on the applying of genomic applied sciences to enhance the understanding of human illnesses and the accuracy of medical diagnoses, prognoses and coverings. Dr. Mardis earned his BS in Zoology and his Ph.D. in chemistry and biochemistry, each from the College of Oklahoma. She has authored over 380 articles in peer-reviewed journals, authored chapters for a number of medical textbooks, and is an elected member of the US Nationwide Academy of Medication.

  • Daniel Shoemaker, Ph.D., former scientific director of Destiny Therapeutics. Dr. Shoemaker has labored within the trade for over 25 years, serving to to construct a number of profitable organizations starting from startups to public corporations. Most lately at Destiny, he led the corporate’s innovation efforts to convey a number of iPSC-derived cell therapies to the clinic. Beforehand, Dr. Shoemaker served as Chief Scientific Officer of ICx Biosystems, a biotechnology firm that developed superior sensing applied sciences to be used in biodefense, most cancers, and prenatal diagnostics. He was additionally a founding scientist of Rosetta Inpharmatics. Dr. Shoemaker earned his BS in Biochemistry from the College of California, Santa Barbara and his Ph.D. in biochemistry from Stanford College.

About Singular Genomics Techniques, Inc.
Singular Genomics is a life sciences expertise firm that leverages novel NGS and multiomics applied sciences to create merchandise that empower researchers and clinicians. Our mission is to speed up genomics for the development of science and medication. Our Singular Sequencing Engine is the elemental platform expertise that varieties the idea of our merchandise in addition to the basics of our merchandise: energy, pace, flexibility and precision. We’re at present growing two merchandise particularly designed to focus on purposes the place these primary product rules are most essential. Our first product, the G4, targets the NGS market. Our second product in improvement, the PX, combines single cell evaluation, spatial evaluation, genomics and proteomics in a single built-in instrument to ship a flexible multiomics resolution.

Ahead-looking statements
Sure statements contained on this press launch, apart from historic info, could represent forward-looking statements throughout the that means of the federal securities legal guidelines. These forward-looking statements are based mostly on our administration’s present expectations and are topic to a lot of dangers and uncertainties that might trigger our precise future outcomes to vary materially from our administration’s present expectations or these implied by the statements. potential. These and different threat elements that might have an effect on our future working outcomes are recognized and described in additional element in our most up-to-date filings on Varieties 10-Ok and 10-Q and in different filings we make. on occasion with the SEC, together with our Quarterly Report on Type 10-Q for the interval ended March 31, 2022, filed with the SEC on Could 10, 2022. Accordingly, you shouldn’t depend on any forward-looking statements as predictions of future occasions or our future efficiency. Besides as required by relevant legislation, we undertake no obligation to publicly replace or revise any forward-looking statements contained herein, whether or not because of new info, future occasions, change circumstances or in any other case.

Contact Investor
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1 AB
973-271-6085
dan@1abmedia.com

Leave a Reply

Your email address will not be published.